Opioid Peptides Like Enkephalins Could Treat Chronic Eye Pain in Dry Eye Disease | Research

The takeaway

Endogenous opioid peptides (enkephalins, endorphins, dynorphins) modulate eye pain in dry eye disease, and topical formulations containing opiorphin may offer a new treatment for chronic ocular pain.

Endogenous pain relief
The eye has its own opioid peptide system for pain control. Boosting it with opiorphin could provide relief without the side effects of systemic opioids

What the researchers found

Eye pain in dry eye disease is modulated by endogenous opioid peptides. Peripheral and central sensitization causes pain persistence. Topical opiorphin-containing formulations represent a novel theoretical approach to treat ocular pain by enhancing endogenous enkephalin activity.

Why it matters

Chronic eye pain affects millions of dry eye sufferers and is notoriously difficult to treat. Leveraging the eye's own opioid peptide system through topical formulations could provide a fundamentally new treatment approach without systemic opioid side effects.

The numbers in context

Pain progression: peripheral then central sensitization; endogenous opioids: enkephalins, endorphins, dynorphins; novel: opiorphin-based protein-GAG complex topical agent

How the study worked

Narrative review of pain pathophysiology in dry eye disease, focusing on peripheral and central sensitization mechanisms and the role of endogenous opioid peptides in ocular pain modulation.

Who was studied

Review of dry eye disease pain pathophysiology and opioid peptide treatment potential

What this study cannot tell us

Review with theoretical therapeutic proposals. Opiorphin-based eye drops are not yet validated in clinical trials. Efficacy and safety of topical opioid peptide modulation in dry eye patients are unknown.

How to read the evidence

Not applicable (narrative review). Theoretical therapeutic proposals based on known opioid peptide biology. Clinical validation needed.

When this study was published

Published 2021. Topical opioid peptide modulators for eye pain are in early research stages.

The bigger picture

This connects neuropeptide biology to a common, underserved medical problem. Topical opioid peptide modulation could become a new class of eye treatment, and the principle of boosting endogenous pain-relief peptides (rather than adding exogenous opioids) has applications beyond ophthalmology.

Questions still open

Would topical opiorphin effectively reduce dry eye pain without side effects?
Can central sensitization in chronic dry eye be reversed by peripheral opioid peptide modulation?
Could enkephalin-boosting eye drops replace current anti-inflammatory dry eye treatments?

Common questions

Why does dry eye cause so much pain?

Chronic dry eye damages nerve endings on the eye surface. Over time, the nervous system becomes sensitized, amplifying pain signals. In severe cases, patients feel significant pain even when their eyes appear normal — a condition called central sensitization.

Could opioid-based eye drops help with dry eye pain?

Potentially. The eye naturally uses opioid peptides (enkephalins) to control pain. Opiorphin is a peptide that prevents their breakdown. Topical eye drops containing opiorphin could boost this natural system, providing pain relief without the addiction risks of systemic opioids.

Read the original research

New Perspectives in the Pathophysiology and Treatment of Pain in Patients with Dry Eye Disease.

Journal of clinical medicine, 11(1)

View on PubMed ↗Publisher’s paper ↗

Citation

Giannaccare, Giuseppe; Ghelardini, Carla; Mancini, Alessandra; Scorcia, Vincenzo; Di Cesare Mannelli, Lorenzo. (2021). New Perspectives in the Pathophysiology and Treatment of Pain in Patients with Dry Eye Disease.. Journal of clinical medicine, 11(1). https://doi.org/10.3390/jcm11010108